Published in Chest on September 01, 2006
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med (2016) 2.06
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.95
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res (2013) 1.86
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2007) 1.25
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol (2011) 1.21
Improving physical activity in COPD: towards a new paradigm. Respir Res (2013) 1.20
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
Implementing chronic care for COPD: planned visits, care coordination, and patient empowerment for improved outcomes. Int J Chron Obstruct Pulmon Dis (2011) 1.04
Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. Chest (2011) 1.03
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol (2015) 0.97
Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker? Front Pharmacol (2011) 0.94
Impact of nutritional status on body functioning in chronic obstructive pulmonary disease and how to intervene. Curr Opin Clin Nutr Metab Care (2008) 0.90
Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD. Pulm Med (2013) 0.89
Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies. Respir Res (2016) 0.88
Activity restriction in mild COPD: a challenging clinical problem. Int J Chron Obstruct Pulmon Dis (2014) 0.88
Impact of bronchodilator therapy on exercise tolerance in COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.86
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis (2009) 0.86
Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD? Respir Res (2011) 0.85
Inspiratory Capacity during Exercise: Measurement, Analysis, and Interpretation. Pulm Med (2013) 0.83
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J (2010) 0.82
Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.81
COPD: maximization of bronchodilation. Multidiscip Respir Med (2014) 0.80
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Patient-Centered Medical Home in chronic obstructive pulmonary disease. J Multidiscip Healthc (2011) 0.79
Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients. BMC Pulm Med (2014) 0.78
Assessing the exercise response to a bronchodilator in COPD: time to get off your bike? Thorax (2007) 0.78
Worse Prognosis for Stage IA Lung Cancer Patients with Smoking History and More Severe Chronic Obstructive Pulmonary Disease. Ann Thorac Cardiovasc Surg (2015) 0.76
Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. PLoS One (2015) 0.75
Assessment of patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 0.75
The measurement of lung volumes using body plethysmography and helium dilution methods in COPD patients: a correlation and diagnosis analysis. Sci Rep (2016) 0.75
Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. J Altern Complement Med (2017) 0.75
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 7.67
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest (2007) 5.01
The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol (1985) (2008) 4.33
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med (2006) 3.71
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med (2008) 2.79
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol (2004) 2.33
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med (2010) 2.06
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.97
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med (2008) 1.89
Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J (2011) 1.83
Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med (2009) 1.79
Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. Am J Respir Crit Care Med (2009) 1.78
Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol (1985) (2006) 1.76
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Ventilatory and perceptual responses to cycle exercise in obese women. J Appl Physiol (1985) (2007) 1.67
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax (2007) 1.61
Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage (2011) 1.59
Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med (2013) 1.59
Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc (2007) 1.56
Effect of obesity on respiratory mechanics during rest and exercise in COPD. J Appl Physiol (1985) (2011) 1.53
Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med (2002) 1.49
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD (2009) 1.49
Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD (2004) 1.46
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med (2013) 1.41
Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.38
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest (2002) 1.23
Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration (2010) 1.22
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest (2007) 1.15
Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest (2014) 1.15
Measuring the effects of COPD on the patient. Respir Med (2005) 1.13
Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med (2010) 1.13
Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med (2010) 1.11
Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med (2011) 1.11
Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology (2011) 1.09
Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD (2010) 1.09
Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol (2009) 1.08
Minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med (2013) 1.06
Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J (2011) 1.06
The COPD Biomarker Qualification Consortium (CBQC). COPD (2013) 1.06
Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med (2008) 1.05
Sex differences in exertional dyspnea in patients with mild COPD: physiological mechanisms. Respir Physiol Neurobiol (2011) 1.04
Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. COPD (2012) 1.04
Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol (2002) 1.03
Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest (2011) 1.02
Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol (2003) 1.02
Inflammation in COPD: implications for management. Am J Med (2012) 1.00
Recent advances in dyspnea. Chest (2015) 0.99
Complications of lung resection and exercise capacity: a meta-analysis. Respir Med (2007) 0.98
Cardiopulmonary exercise testing: relevant but underused. Postgrad Med (2010) 0.97
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res (2011) 0.96
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther (2008) 0.96
Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax (2011) 0.95
Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. Eur Respir J (2013) 0.95
Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest (2004) 0.94
Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.94
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. Am J Respir Crit Care Med (2009) 0.91
Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab (2013) 0.91
Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am J Respir Crit Care Med (2011) 0.91
A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med (2004) 0.91
Effects of lung volume reduction surgery on gas exchange and breathing pattern during maximum exercise. Chest (2009) 0.90
Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. COPD (2013) 0.90
Effect of obesity on constant workrate exercise in hyperinflated men with COPD. BMC Pulm Med (2010) 0.90
Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc (2006) 0.88
Sex differences in the perceived intensity of breathlessness during exercise with advancing age. J Appl Physiol (1985) (2008) 0.87
Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res (2011) 0.87
Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med (2013) 0.87
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung (2011) 0.87
Characterizing functional lung heterogeneity in COPD using reference equations for CT scan-measured lobar volumes. Chest (2013) 0.86
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med (2011) 0.86
The efficacy and safety of cilomilast in COPD. Drugs (2008) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Physiologic characterization of the chronic bronchitis phenotype in GOLD grade IB COPD. Chest (2015) 0.85
Respiratory Consequences of Mild-to-Moderate Obesity: Impact on Exercise Performance in Health and in Chronic Obstructive Pulmonary Disease. Pulm Med (2012) 0.85
Mechanical ventilatory constraints during incremental cycle exercise in human pregnancy: implications for respiratory sensation. J Physiol (2008) 0.85